Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
MWN-AI** Summary
Anixa Biosciences Inc., a biotechnology firm focused on innovative cancer treatments, has announced that Dr. Jose Conejo-Garcia, a prominent figure in immunology from Duke University, will serve as the keynote speaker at the South Carolina Clinical & Translational Research Institute 2026 Retreat. Scheduled for March 6, 2026, the retreat aims to foster collaboration among pioneers in research, clinical care, and industry, focusing on advances in cell-based therapies, immunotherapy, oncology, and cellular product manufacturing.
Dr. Conejo-Garcia, who is also the co-inventor of Anixa's groundbreaking FSHR-mediated CAR-T therapy, will deliver insights into the company’s ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel). This innovative therapy targets the follicle-stimulating hormone receptor (FSHR), which is selectively present in ovarian cancer cells. The trial is designed for adult women suffering from recurrent ovarian cancer who have already undergone multiple therapies.
The SCTR 2026 Retreat is set to be a significant gathering, integrating discussions about breakthrough innovations in the ever-evolving landscape of cancer treatment. Anixa, in collaboration with institutions like the Moffitt Cancer Center, is making strides in developing lira-cel, which utilizes a distinct form of CAR-T technology aimed at leveraging the body’s immune response to combat cancer.
Anixa's portfolio also includes several vaccine projects, in partnership with the Cleveland Clinic, targeting various forms of cancer. The company's strategic focus on immune therapies and partnerships with leading research institutions underscores its commitment to developing pioneering solutions in cancer treatment. For further details, visit Anixa's website or their social media profiles.
MWN-AI** Analysis
Anixa Biosciences (NASDAQ: ANIX) is making strides in the biotechnology sector, particularly with its innovative approach to cancer treatment through CAR-T therapies. The announcement that Dr. Jose Conejo-Garcia, a key figure behind Anixa's FSHR-mediated CAR-T technology, will keynote the upcoming South Carolina Clinical & Translational Research Institute 2026 Retreat is significant for multiple reasons.
Firstly, the visibility provided by such an event positions Anixa at the forefront of discussions on groundbreaking cell-based therapies, particularly in oncology. The retreat will serve as a platform for Anixa to showcase its ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel), designed for recurrent ovarian cancer. The uniqueness of lira-cel, which selectively targets the follicle-stimulating hormone receptor (FSHR), may translate into expanded investor interest, especially as potential efficacy becomes clearer with ongoing trials.
Investors should consider the implications of fostering collaborations with prestigious institutions like Duke University. This not only enhances Anixa's credibility but also boosts its research capabilities and access to cutting-edge developments. The partnership with Moffitt Cancer Center underscores its commitment to partnership-driven innovation, which may yield more robust and viable therapeutic offerings.
Looking ahead, the positive sentiment surrounding Anixa's presentations and trial updates could bolster stock performance, particularly if preliminary trial results are promising. However, investors must remain mindful of the inherent risks associated with biotechnology investments, as clinical outcomes can be unpredictable, and regulatory approval processes are rigorous.
In conclusion, Anixa Biosciences presents a compelling investment opportunity amid the rising demand for innovative cancer therapies, especially with its novel CAR-T approaches. Keeping an eye on upcoming clinical results and market reactions will be essential for potential stakeholders in this dynamic and rapidly evolving sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
PR Newswire
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology
SAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine and the co-inventor of Anixa's CAR-T technology, will be a keynote speaker at the South Carolina Clinical & Translational Research (SCTR) Institute 2026 Retreat: Cell-Based Therapies from Discovery to Translation, on Friday, March 6, 2026.
Dr. Conejo-Garcia's keynote presentation will include a discussion of Anixa's ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, which utilizes the FSHR-mediated CAR-T therapy first discovered by Dr. Conejo-Garcia and his team at The Wistar Institute.
The SCTR 2026 Retreat will bring together pioneers in research, clinical care, and industry to showcase breakthrough innovations in advanced cell therapy, immune therapy, oncology, and cellular product manufacturing, and engage in empowering collaboration across the vibrant ecosystem, driving the future of medicine.
About Lira-cel, Anixa's CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
SOURCE Anixa Biosciences, Inc.
FAQ**
How does Anixa Biosciences Inc. ANIX plan to leverage Dr. Jose Conejo-Garcia's expertise in FSHR-mediated CAR-T therapy to enhance the ongoing Phase 1 clinical trial of lira-cel for recurrent ovarian cancer?
What key insights does Anixa Biosciences Inc. ANIX expect Dr. Conejo-Garcia to share during his keynote at the SCTR 20Retreat regarding the translation of cell-based therapies from research to clinical applications?
How does Anixa Biosciences Inc. ANIX intend to capitalize on the collaboration with Moffitt Cancer Center and the innovations presented at the SCTR Retreat to further develop its CAR-T technology and cancer vaccines?
What are the potential implications of Dr. Conejo-Garcia's keynote presentation for investors in Anixa Biosciences Inc. ANIX, particularly in relation to the market outlook for CAR-T therapies and its clinical pipeline?
**MWN-AI FAQ is based on asking OpenAI questions about Anixa Biosciences Inc. (NASDAQ: ANIX).
NASDAQ: ANIX
ANIX Trading
1.42% G/L:
$2.86 Last:
53,572 Volume:
$2.93 Open:
